Partners
InSphero partners with leading biotechnological and pharmaceutical companies, academic institutions, and research organizations to advance scientific research and drug development. Through these collaborations, we drive further the development of scalable, reliable, and reproducible 3D cell-based solutions that help researchers yield pragmatic and actionable insights for better and faster decisions.
Industry Partners
InSphero has established dynamic partnerships with biotechnological companies, marking a crucial stride in advancing cutting-edge drug research and development. Through joint efforts, we converge our strengths to create industry-ready platforms and solutions that mimic human biology more accurately, thus revolutionizing preclinical testing, drug efficacy evaluation, and toxicity assessments.
ATCC
ATCC and InSphero have formed a strategic partnership that is set to redefine standards and introduce new paradigms in the rapidly evolving field of 3D cell–based oncology research.
By combining the power of ATCC's gold-standard, authenticated cell lines with InSphero's innovative, industry-leading 3D cell-based assay platforms, the scientific community will gain unprecedented access to assay-ready 3D tumor microtissues that will help accelerate oncology research at a global scale. This partnership will also provide an expansive and diverse portfolio of tumor models in easy-to-use and workflow-ready formats, ensuring researchers have access to enriched data sets that underpin better decision-making in drug safety and efficacy.
Read the press release to learn more about the partnership
Biognosys
Biognosys is a leading proteomics company, providing superior technology and software for highly multiplexed protein quantification. Biognosys has partnered closely with us to provide high-sensitivity and specificity proteomics analysis to characterize our 3D InSight™ Microtissue functionality and provide ground-breaking insights into toxicity and efficacy omics applications.
Breakthrough T1D (JDRF)
Breakthrough T1D (formerly JDRF) is the leading global organization focused on type 1 diabetes (T1D) research and advocacy. Through its Industry Discovery & Development Partnerships (IDDP) program, Breakthrough T1D is supporting InSphero in a collaborative project with the ULB Center for Diabetes Research. Together, we aim to identify novel therapeutic strategies that protect insulin-producing beta cells from autoimmune destruction using InSphero’s advanced 3D islet cell models.
Read the press release to learn more about the partnership
Hamilton
Hamilton Bonaduz AG is a leading global manufacturer for automated workstations for liquid handling and laboratory automation technology to the scientific community. Hamilton products are known for their advances in life sciences and biotechnology, offering reliability, performance and flexibility. We leverage the MagPip™ technology on the Microlab VANTAGE ™, which allows us to do automated fast and accurate liquid transfer in our proprietary spheroid microplates.
Hesperos
Hesperos is a pioneer in human-on-a-chip and microphysiological systems (MPS), offering single- and multi-organ platforms for predictive drug safety and efficacy testing. Our strategic collaboration combines Hesperos’ systems-level functional models with InSphero’s scalable 3D spheroid and organoid technologies, enabling pharmaceutical and biotech partners to access integrated, end-to-end solutions for drug discovery and toxicology.
Read the press release to learn more about the partnership
INTEGRA
INTEGRA is a leading provider of high-quality laboratory tools for liquid handling, media preparation, sterilization, and cell cultivation. The company commits to creating innovative solutions which that fulfill the customer needs in research, diagnostics, and quality control within the life science markets and medical industry. Our partnership with INTEGRA is based on providing high-performance liquid-handling solutions for 3D cell culture.
Kolaido
The IKOSA Platform empowers life science researchers with an intuitive, no-code AI solution for bioimage analysis. It enables the creation of custom analysis apps, automating workflows to enhance efficiency while ensuring unbiased, accurate results. Insphero’s 3D microtissues contain extensive information on human physiology and disease states and how treatments impact them. With the IKOSA Platform, we have a tool that allows us to extract insights in a fast and reliable way.
Promega Corporation
One of the world’s most trusted providers of luminescent and fluorescent-based assay providers, Promega has worked closely with us since 2010 to validate and optimize assays for use with 3D microtissues, including CellTiter-Glo® ATP assays, LDH and apoptosis assays, as well as high-quality RNA extraction from InSphero microtissues.
Tessara Therapeutics
Tessara is an Australian biotech company developing validated 3D neuronal microtissues for CNS research. Through our partnership, InSphero offers these models as part of our 3D portfolio to support neurotoxicity and neurodegeneration studies.
Read the press release to learn more about the partnership
Yokogawa
We partner with Yokogawa to develop methods for imaging and analysis of 3D and 4D microtissues using the CellVoyager™ High-Content Imaging family of products, including the bench-top CQ1 instrument as well as the high-throughput CV8000 system for advanced toxicology and efficacy testing applications. Image acquisition is supplemented by the analysis software suite CellPathfinder™, which incorporates machine learning and deep learning.
Academic Partners
InSphero's collaboration with esteemed academic institutions underscores our dedication to advancing scientific frontiers. These partnerships facilitate the exchange of knowledge, resources, and expertise, fostering a fertile ground for innovation with the potential to shape the future of drug development.
Erasmus University Medical Center
Prof. Dr. Wytske van Weerden, Associate professor of Experimental Urology and an expert in prostate cancer.
ETH Zürich, Switzerland
Prof. Dr. Andreas Hierlemann, Full Professor at the Department of Biosystems Science and Engineering
Goethe University Frankfurt, Germany
Prof. Dr. Ernst Stelzer, Institute of Cell Biology and Neuroscience
University of Bern
Dr. sc. nat. Christian Zuppinger, Department of Clinical Research, Cardiovascular Research Group
R&D Publicly-funded projects
InSphero's engagement with publicly funded R&D projects exemplifies our commitment to driving innovation in a collaborative ecosystem. We contribute our expertise to accelerate the development of breakthrough solutions and amplify their reach and impact. By bridging the gap between academia, industry, and public sector research, InSphero plays a pivotal role in shaping the landscape of research that holds the potential to transform multiple facets of human health and scientific understanding.
PATROLS - Physiologically Anchored Tools for Realistic nanOmateriaL hazard aSsessment
PATROLS is an international project combining a team of academics, industrial scientists, government officials and risk assessors to deliver advanced and realistic tools and methods for nanomaterial safety assessment
UNLOOC - Unlocking data content of Organ-on-Chips
UNLOOC is a Chips JU initiative uniting 51 partners across Europe to industrialize organ-on-chip systems using AI and advanced analytics. InSphero leads a €12M use case to develop diverse, cryopreservable 3D in vitro organ models for inclusive drug testing.
Regulatory & Nonprofit Partners
InSphero's strategic partnerships with Governmental and Nonprofit organizations underscore its leadership in advancing regulatory acceptance and ethical use of human-relevant 3D in vitro models, accelerating safer drug testing and reducing reliance on animal studies.
PCRM - Physicians Committee for Responsible Medicine
PCRM is a U.S.-based nonprofit advancing ethical, human-relevant research and medical practices. Together with InSphero, PCRM co-founded the HUMAIN Award to support scientists developing innovative, non-animal 3D in vitro models for drug discovery and safety testing.
Memberships
As a member of prestigious life science organizations, InSphero is actively involved in the advancement of drug discovery science, demonstrating our commitment to fostering continuous discussions and knowledge-sharing. By participating in these organizations, we collaborate with thought leaders, experts, and industry peers, which enhances the mutual ability to stay at the forefront of emerging trends and technologies.
Swiss Biotech Association
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.
Toolpoint for Lab Science
Toolpoint for Lab Science is a vertically integrated cluster that brings together the skills and expertise of the laboratory automation industry in Europe. Founded in 2003 by companies in the Greater Zurich Area, it now brings together companies, universities, research institutes and partners with the aim of making lab processes more effective and efficient – from sample collection to the use of results.
The Society for Laboratory Automation and Screening (SLAS)
The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation technology and tools. In 2023, InSphero’s CEO and Co-founder, Dr. Jan Lichtenberg was appointed as the President of the SLAS Board of Directors.
Society of Toxicology
Founded in 1961, the Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology.
International MPS Society
IMPSS is a global initiative dedicated to uniting stakeholders, facilitating knowledge exchange, and promoting education to advance microphysiological systems (MPS). By fostering collaboration, harmonization, and training, IMPSS supports the responsible global adoption of MPS technologies. InSphero CEO and Co-founder Dr. Jan Lichtenberg serves on the organization’s Governing Board.
SBI² - The Society of Biomolecular Imaging and Informatics
The Society of Biomolecular Imaging and Informatics (SBI2) is an international community of leaders, scientists, and students promoting technological advancement, discovery, and education to quantitatively interrogate biological models to provide high context information at the cellular level.